title: [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
abstract: Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method. A 4-month treatment has shown that both types of therapy had a significant clinical effect, however clinical effect proved to be more higher and stable in patients treated with cerebrolysin. A number of responders in the cerebrolysin group was 1.7-fold higher comparing to that in the exelon group. Patients with the ApoE4(+) genotype did not differ in response to either drug but in those with genotype ApoE4(-) the number of responders was 3-fold higher in the group treated with cerebrolysin compared to the group given exelon. A follow-up estimation of cognitive impairment in ApoE4(-) patients revealed that long-term clinical effect of cerebrolysin treatment was 6.5 times higher than that of exelon.
authors.forename: S I
authors.initials: SI
authors.lastname: Gavrilova
authors.forename: I V
authors.initials: IV
authors.lastname: Kolykhalov
authors.forename: G I
authors.initials: GI
authors.lastname: Korovaĭtseva
authors.forename: G A
authors.initials: GA
authors.lastname: Zharikov
authors.forename: Ia B
authors.initials: IaB
authors.lastname: Kalyn
authors.forename: N D
authors.initials: ND
authors.lastname: Selezneva
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D000596:Amino Acids / Q000627:therapeutic use*; D001057:Apolipoproteins E / Q000235:genetics*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000378:metabolism*; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D000068836:Rivastigmine
chemical_list: D000596:Amino Acids; D001057:Apolipoproteins E; D002800:Cholinesterase Inhibitors; D009414:Nerve Growth Factors; D018697:Nootropic Agents; D048448:Phenylcarbamates; C006952:cerebrolysin; D000068836:Rivastigmine